ArticleJournal for immunotherapy of cancer2026
Targeting the novel immune checkpoint KLRG1 is markedly therapeutic against cancer through multiple lymphocyte subsets.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCheckpoint blockade therapies have demonstrated clinical benefit across multiple cancer types; however, many patients with immune cell infiltration remain non-responsive or develop resistance. This suggests that additional, unidentified regulatory pathways limit treatment efficacy. The purpose of this study was to investigate the role of the inhibitory receptor KLRG1 in limiting antitumor immunity and to evaluate its potential as a therapeutic target in patients refractory to first-generation checkpoint inhibitors.
methodsThe study used murine models to observe KLRG1 expression following checkpoint therapy and analyzed tumor-infiltrating T cells from patients with melanoma non-responsive to anti-programmed death-1 (PD-1). We generated KLRG1 knockout mice and B16 melanoma N-cadherin (KLRG1 ligand) deletions to assess tumor growth. Additionally, a KLRG1 human knock-in mouse model and a novel anti-human KLRG1 monoclonal antibody (mAb) were developed and tested both in vitro and in vivo.
resultsKLRG1 was found to be upregulated on murine CD8+T cells post-therapy, and high KLRG1 expression correlated with anti-PD-1 resistance in patients with melanoma. KLRG1 knockout mice showed significantly reduced tumor growth, a response dependent on CD8
conclusionsOur findings demonstrate KLRG1 as a critical negative regulator of antitumor immunity and support KLRG1-cadherin blockade as a promising strategy for improving immunotherapy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.